Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. (21st June 2018)

• Record Type: Journal Article
• Authors: Radocha, Jakub; Maisnar, Vladimír; Pour, Luděk; Špička, Ivan; Minařík, Jiři; Szeligová, Lenka; Pavlíček, Petr; Jungová, Alexandra; Krejčí, Marta; Pika, Tomáš; Straub, Jan; Brožová, Lucie; Stejskal, Lukáš; Heindorfer, Adriana; Jindra, Pavel; Kessler, Petr; Mikula, Peter; Sýkora, Michal; Wróbel, Marek; Jarkovský, Jiří; Hájek, Roman
• Is Part Of: Cancer medicine. Volume 7:Number 8(2018:Aug.)
• Page Start: 4132
• Page End: 4145
• Publication Date: 2018-06-21
• Subjects: Czech Myeloma Group Registry -- monoclonal gammopathies -- multiple myeloma -- overall survival -- real‐world -- risk stratification; 616.994005
• DOI: 10.1002/cam4.1620
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R‐ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R‐ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5‐55.9) and 46.2 (95% CI: 38.9‐53.5) months from diagnosis and initiation of first‐line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5‐40.3) vs 58.3 (95% CI: 53.8‐62.9) months in high‐risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2‐38.0) vs 47.2 (95% CI: 43.4‐51.0) months in Stage III vs Stage II patients (R‐ISS; P < .001). In conclusion, IMWG and R‐ISS risk stratification indices are applicable to patients with MM in a real‐world setting. Abstract : We have successfully validated R‐ISS myeloma prognostic score on real‐life unselected population. The system can be broadly applicable outside clinical trials.